Warning letter wave
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as December 10, 2024. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
FDA warning letters dated December 10, 2024 told four online sellers of GLP-1 products labelled for research that their products were unapproved new drugs intended for human use.
The recipients were Xcel Peptides (Xcel Research LLC), SwissChems, Summit Research Peptides and Prime Peptides (Prime Vitality Inc.). The products named across the letters include semaglutide, tirzepatide and retatrutide. The SwissChems letter states: “Despite statements on your product labeling marketing your products as ‘research chemicals only,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” FDA posted the four letters on December 17, 2024, alongside a letter to Veronvy over oral GLP-1 products. A law-firm review called them the first FDA warning letters it had seen for GLP-1s labelled “for research use only and not for human consumption or clinical use”.
Evidence tier: Official or peer-reviewed record.
Sources: FDA warning letters to SwissChems (archived copy), Summit Research Peptides, Prime Peptides and Xcel Research; FDA Roundup, December 17, 2024 (archived copy); Foley & Lardner, December 18, 2024.